Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Phase 2 Recruiting
30 enrolled
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Phase 2 Recruiting
30 enrolled
MK-1026-003
Phase 2 Recruiting
490 enrolled
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Phase 2 Recruiting
496 enrolled
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Phase 2 Recruiting
132 enrolled
TAPUR
Phase 2 Recruiting
4,200 enrolled
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
Phase 2 Recruiting
27 enrolled
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase 2 Recruiting
100 enrolled
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Phase 2 Recruiting
115 enrolled
CAPTUR
Phase 2 Recruiting
720 enrolled
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
Phase 2 Recruiting
49 enrolled
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Phase 2 Recruiting
28 enrolled
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Phase 2 Recruiting
31 enrolled
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Phase 2 Recruiting
35 enrolled
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Phase 2 Recruiting
216 enrolled
ENABLE-2
Phase 2 Recruiting
60 enrolled
SOUNDTRACK-B
Phase 2 Recruiting
240 enrolled
Epco, Zanu, Ritux for R/R FL or MZL
Phase 2 Recruiting
45 enrolled
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Phase 2 Recruiting
24 enrolled
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Phase 2 Recruiting
54 enrolled
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
Phase 2 Recruiting
22 enrolled
Amping up With PemJAK
Phase 2 Recruiting
53 enrolled
HSCT
Phase 2 Recruiting
100 enrolled
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Phase 2 Recruiting
28 enrolled
Personalized NK Cell Therapy in CBT
Phase 2 Recruiting
100 enrolled
Auto Stem Cell Transplant for Lymphoma Patients
Phase 2 Recruiting
150 enrolled
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Phase 2 Recruiting
78 enrolled
Two Step Haplo With Radiation Conditioning
Phase 2 Recruiting
63 enrolled
JASPIS-01
Phase 2 Recruiting
178 enrolled
Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL
Phase 2 Recruiting
180 enrolled
Cord Blood Transplant in Adults With Blood Cancers
Phase 2 Recruiting
54 enrolled
MTR²
Phase 2 Recruiting
20 enrolled
O-ICE
Phase 2 Recruiting
25 enrolled
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Phase 2 Recruiting
20 enrolled
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Phase 2 Recruiting
20 enrolled
RADICAL
Phase 2 Recruiting
80 enrolled
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Phase 2 Recruiting
39 enrolled
DALY II USA/ MB-CART2019.1 for DLBCL
Phase 2 Recruiting
248 enrolled
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Phase 2 Recruiting
31 enrolled
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
Phase 2 Recruiting
33 enrolled
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Recruiting
60 enrolled
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
Phase 2 Recruiting
12 enrolled
VitaStem
Phase 2 Recruiting
220 enrolled
Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies
Phase 2 Recruiting
20 enrolled
CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma
Phase 2 Recruiting
36 enrolled
TMF-Allo
Phase 2 Recruiting
150 enrolled
STELLAR
Phase 2 Recruiting
105 enrolled
HLA
Phase 2 Recruiting
114 enrolled